July 15, 2020 – August 14, 2020 Online: On-demand
CE: 9.65 Contact Hours
including 9.65 hours of pharmacology
Due to the continued prevalence of the coronavirus (COVID-19) the 2020 AANP Pharmacology Update (originally scheduled for April 2020) has been reformatted as an online activity via the AANP CE Center. Each of the conference’s six sessions will be made available as individual, on-demand webinars for convenient viewing at your own pace and according to your own schedule between July 15 – August 14, 2020. These sessions will be exclusively available in the AANP CE Center. You will be contacted via email when the sessions are available for viewing. Please Note: If you register for this activity after the designated start date (July 15), it could take up to 24 hours before you see the activity appear in your CE Center Activities list.
AANP understands the importance of pharmacology education. That's why, as a leading provider of continuing education (CE) for nurse practitioners (NPs), AANP is presenting this online pharmacology opportunity focused on primary care.
Register for the 2020 AANP Pharmacology Update to:
Log in with your aanp.org username and password and follow the simple online instructions.
If you have additional question about registration, please contact AANP:
9 a.m.–5 p.m. Monday through Friday, excluding holidays
Mail: American Association of Nurse Practitioners
P.O. Box 12846
Austin, TX 78711
Full refunds of the conference registration fee will be granted if requested up to and including Tuesday, July 14, 2020. No refunds will be given after the conference begins on Wednesday, July 15, 2020.
To cancel your conference registration, you must submit written notice via email to firstname.lastname@example.org.
An administrative fee of $35 will be charged for all checks returned to AANP for insufficient funds.
Alan P. Agins, PhD
Dr. Alan Agins received a Master of Science in Pharmacology and Toxicology and a doctorate in Pharmaceutical Sciences from the University of Rhode Island.
He has held faculty appointments at Warren Alpert Medical School of Brown University, Northeastern University School of Pharmacy and the University of Virginia School of Nursing, as well as visiting faculty or adjunct professorship status in a number of NP programs around the country, including the University of Arizona, Virginia Commonwealth University, Pennsylvania State University, Idaho State University, West Virginia University and Radford University. During his tenure at Brown, Dr. Agins was the recipient of the Dean's Teaching Excellence Award for five consecutive years for his insightful and engaging lectures.
Over the past 25 years, Dr. Agins has presented CE programs nationally on all topics related to pharmacology and pathophysiology to more than 95,000 advanced practice clinicians and allied health care professionals, including more than 130 three-credit-hour or 30- to 45-contact-hour pharmacology courses to NPs seeking to attain or maintain prescriptive authority.
For the past five years, he has been a content contributor to, and national presenter of, the FDA's Opioids REMS CE program for nurses and NPs under the auspices of the Collaborative for REMS Education (CO*RE). He also created a website and online streaming video version of that program for the Nurse Practitioner Healthcare Foundation.
Dr. Agins has authored three books, co-authored textbook chapters, written CE monographs and newsletters and produced pharmacology educational DVDs for nursing associations as well as for corporate pharmacies. He has also presented more than 400 live CE webinars to pharmacists, nationally and internationally, over the past 11 years.
After registering, you will be contacted via email once the sessions are available for viewing.
This presentation is an examination of primary care drugs that received FDA approval between 2018 and 2020. Within this framework will be a discussion of the basic and clinical pharmacology of each new drug, its benefits or limitations compared to similar or existing medications in the same class and, where applicable, where it fits into current clinical usage. Furthermore, we will look at any newer indications for existing medications, newer generic approvals and any pertinent newer treatment guidelines.
This presentation is a review of the recognized, as well as subtle, pharmacodynamic and pharmacokinetic differences between the most widely used opioid analgesics in pain management with special emphasis on the importance of those differences in drug safety, efficacy and tolerability for any given patient. The presentation will include a discussion of patient variability and specific opioid agent differences that can impact clinical outcomes, including the role of potency and differences between agents with respect to metabolism (pharmacogenetics, drug interactions, etc.) as well as the importance of renal function with select agents.
This presentation provides a review and update on the basic and clinical pharmacology of non-opioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen and adjunct drugs, such as antidepressants, antiepileptics and topicals, with emphasis on opioid-sparing treatment options. We will discuss aspects of appropriate patient selection, options for cardiovascular and/or gastrointestinal (GI) risk reduction from NSAIDs, including use of cyclooxygenase-2s (COX-2s), topical NSAIDs and concurrent use of medications such as histamine 2 (H2), blockers, proton pump inhibitors (PPIs) and low-dose aspirin. We also will examine the mechanisms of action and rationale for use of select antiepileptics and antidepressants used as monotherapy or as add-on therapy in the treatment of neuropathic and other chronic pain conditions.
This presentation is a review and update of the basic and clinical pharmacology of medications (antidepressants, antipsychotics, mood stabilizers, etc.) used in the treatment of psychopathological disorders. Emphasis will be placed on newer insights and changes in our understanding of the neuropathological basis of those disorders, including the recognition of newer drug targets and the development of agents that have a better “balance” between efficacy and tolerability.
This presentation is an overview and update on the basic and clinical pharmacology of medical marijuana, including pharmacodynamics and pharmacokinetics of tetrahydrocannabinol (THC) and CBD, legal and medical differences between cannabis and hemp-derived CBD, potential interactions with prescription medications, existing clinical data on the benefits, side effects and dangers of cannabis-related products, the current health concerns surrounding ”vaping” and other important considerations for both health care providers and patients regarding the use of cannabis for medical or recreational purposes.
This presentation is a review and update of the basic and clinical pharmacology of medications used in the treatment of cardiovascular disorders, including antihypertensives, anticoagulants, drugs for heart failure, atrial fibrillation, deep vein thrombosis (DVT) treatment and prevention. Additionally, there will be an update on treatment guidelines for the above disorders, where applicable.